# SMURF2

## Overview
SMURF2, or SMAD specific E3 ubiquitin protein ligase 2, is a gene that encodes a protein belonging to the HECT family of E3 ubiquitin ligases. This protein plays a pivotal role in the regulation of the TGF-β signaling pathway by targeting specific proteins for ubiquitination and subsequent proteasomal degradation. The SMURF2 protein is characterized by its C2-WW-HECT domain structure, which facilitates its interaction with various substrates and regulatory proteins (Bai2020The; Osmundson2009Smurf2). Functionally, SMURF2 is involved in critical cellular processes such as proliferation, differentiation, and apoptosis, and it acts as a negative regulator of TGF-β signaling by promoting the degradation of receptor-regulated Smads and other signaling components (Zhang2001Regulation; Lin2000Smurf2). The protein's activity is modulated by post-translational modifications, including neddylation and SUMOylation, which are essential for its role in maintaining cellular homeostasis and its involvement in various diseases, particularly cancer (Bai2020The).

## Structure
Smurf2 is a C2-WW-HECT type E3 ubiquitin ligase located on chromosome 17. The protein consists of three main regions: a C2 domain at the N-terminal, three WW domains, and a highly conserved HECT catalytic domain at the C-terminal (Bai2020The). The C2 domain is involved in membrane binding, while the WW domains, each containing two conserved tryptophan residues, are responsible for substrate recognition through specific binding to a PPXY motif (Bai2020The). The HECT domain is crucial for the catalytic activity of ubiquitin transfer (Osmundson2009Smurf2).

In its resting state, the C2 domain associates with the HECT domain to prevent the WW domain from interacting with substrates, maintaining stable expression of Smurf2 in cells. This autoinhibition is essential for Smurf2's function (Bai2020The). Smurf2 undergoes various post-translational modifications, including neddylation, which enhances its E3 ligase activity and promotes its degradation, as well as SUMOylation, phosphorylation, and methylation, which regulate its activity and stability (Bai2020The). These modifications are crucial for its role in physiological processes and its dysregulation in diseases like cancer (Bai2020The).

## Function
SMURF2 (SMAD specific E3 ubiquitin protein ligase 2) is a critical regulator of the TGF-β signaling pathway, functioning primarily as an E3 ubiquitin ligase. It targets various proteins for ubiquitination and subsequent proteasomal degradation, thereby modulating cellular processes such as proliferation, differentiation, and apoptosis. SMURF2 interacts with receptor-regulated Smads, including Smad1 and Smad2, promoting their degradation and thus regulating the TGF-β/BMP signaling pathways (Zhang2001Regulation; Lin2000Smurf2).

In healthy human cells, SMURF2 plays a role in maintaining cellular homeostasis by acting as a negative regulator of TGF-β signaling. It achieves this by targeting signaling components and downstream proteins, such as the type I TGFβ receptor and R-Smads, for degradation (Bai2020The). SMURF2 also forms a complex with Smad2 to facilitate the degradation of SnoN, a process crucial for the proper regulation of TGF-β signaling (Bonni2001TGF-β).

SMURF2 is active in both the cytoplasm and nucleus, influencing cell cycle regulation and genomic stability. It is involved in processes such as cell migration and mitotic regulation, highlighting its multifaceted role in cell biology (David2014Smurf2; Moore2010The).

## Clinical Significance
Alterations in SMURF2 expression and interactions have significant clinical implications in various cancers. In pancreatic cancer, SMURF2 acts as a tumor suppressor, with its downregulation associated with epithelial-mesenchymal transition (EMT) and gemcitabine resistance. This downregulation leads to increased cell invasion and migration, highlighting its role in drug resistance and tumor progression (ZHANG2015miR15b). In colorectal cancer, SMURF2 targets SIRT1 for degradation, and its depletion results in increased SIRT1 levels, promoting cell migration, proliferation, and metastasis. This suggests that SMURF2 downregulation contributes to colorectal cancer progression (Yu2020Ubiquitinationmediated).

In non-small-cell lung cancer (NSCLC), SMURF2 inhibition enhances sensitivity to chemotherapy and radiation, indicating its potential as a therapeutic target. Increased SMURF2 expression post-treatment is linked to poorer survival outcomes, suggesting its role as a prognostic marker (Chaudhary2022Smurf2). SMURF2 also plays a role in tyrosine kinase inhibitor resistance in lung cancer by stabilizing mutant EGFR, with its overexpression increasing drug tolerance (Ray2020Ubiquitin).

In oral cancer, SMURF2 is identified as a prognostic biomarker, with its expression linked to the immune microenvironment and tumor invasiveness (Deng2024Transcriptome). These findings underscore the complex role of SMURF2 in cancer, with its impact varying based on cancer type and molecular context.

## Interactions
SMURF2, a member of the HECT family of E3 ubiquitin ligases, interacts with various proteins, primarily through its WW domains, which bind to proline-rich PPXY motifs. It interacts efficiently with Smad1 and Smad2, weakly with Smad3, and does not interact with Smad4. The interaction with Smad1 is particularly strong, facilitated by the WW domains of SMURF2 binding to the PPXY motifs in the linker regions of Smads (Zhang2001Regulation). SMURF2 also interacts with Smad7, which acts as an adaptor protein, recruiting SMURF2 to the TGF-β receptor complex and promoting its degradation. This interaction is mediated by the PY motif in Smad7, although mutations in this motif reduce but do not completely abolish the interaction (Kavsak2000Smad7).

In the TGF-β signaling pathway, SMURF2 forms a complex with Smad2 and SnoN, a transcriptional co-repressor. Smad2 recruits SMURF2 to SnoN, facilitating its ubiquitination and degradation. This interaction is dependent on the PY motif of Smad2, which is crucial for SMURF2-dependent ubiquitination of SnoN (Bonni2001TGF-β). SMURF2 also interacts with NEDD9, stabilizing it and preventing its proteasomal degradation, which is essential for the activation of Aurora A kinase during mitosis (Moore2010The).


## References


[1. (Chaudhary2022Smurf2) Kunal R. Chaudhary, Connor J. Kinslow, Haiying Cheng, Jose M. Silva, Jiyang Yu, Tony. J. Wang, Tom K. Hei, Balazs Halmos, and Simon K. Cheng. Smurf2 inhibition enhances chemotherapy and radiation sensitivity in non-small-cell lung cancer. Scientific Reports, June 2022. URL: http://dx.doi.org/10.1038/s41598-022-14448-8, doi:10.1038/s41598-022-14448-8. This article has 4 citations and is from a peer-reviewed journal.](https://doi.org/10.1038/s41598-022-14448-8)

[2. (Moore2010The) Finola E Moore, Evan C Osmundson, Jennifer Koblinski, Elena Pugacheva, Erica A Golemis, Dipankar Ray, and Hiroaki Kiyokawa. The ww-hect protein smurf2 interacts with the docking protein nedd9/hef1 for aurora a activation. Cell Division, September 2010. URL: http://dx.doi.org/10.1186/1747-1028-5-22, doi:10.1186/1747-1028-5-22. This article has 19 citations and is from a peer-reviewed journal.](https://doi.org/10.1186/1747-1028-5-22)

[3. (Kavsak2000Smad7) Peter Kavsak, Richele K. Rasmussen, Carrie G. Causing, Shirin Bonni, Haitao Zhu, Gerald H. Thomsen, and Jeffrey L. Wrana. Smad7 binds to smurf2 to form an e3 ubiquitin ligase that targets the tgfβ receptor for degradation. Molecular Cell, 6(6):1365–1375, December 2000. URL: http://dx.doi.org/10.1016/s1097-2765(00)00134-9, doi:10.1016/s1097-2765(00)00134-9. This article has 1075 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1016/s1097-2765(00)00134-9)

[4. (Deng2024Transcriptome) Lu Deng, Zhihong Wu, Chuanxi Sun, and Zhe Liu. Transcriptome analysis revealed smurf2 as a prognostic biomarker for oral cancer. Journal of Applied Genetics, May 2024. URL: http://dx.doi.org/10.1007/s13353-024-00869-w, doi:10.1007/s13353-024-00869-w. This article has 0 citations and is from a peer-reviewed journal.](https://doi.org/10.1007/s13353-024-00869-w)

[5. (Bonni2001TGF-β) Shirin Bonni, Hong-Rui Wang, Carrie G. Causing, Peter Kavsak, Shannon L. Stroschein, Kunxin Luo, and Jeffrey L. Wrana. Tgf-β induces assembly of a smad2–smurf2 ubiquitin ligase complex that targets snon for degradation. Nature Cell Biology, 3(6):587–595, May 2001. URL: http://dx.doi.org/10.1038/35078562, doi:10.1038/35078562. This article has 423 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1038/35078562)

[6. (Zhang2001Regulation) Ying Zhang, Chenbei Chang, Daniel J. Gehling, Ali Hemmati-Brivanlou, and Rik Derynck. Regulation of smad degradation and activity by smurf2, an e3 ubiquitin ligase. Proceedings of the National Academy of Sciences, 98(3):974–979, January 2001. URL: http://dx.doi.org/10.1073/pnas.98.3.974, doi:10.1073/pnas.98.3.974. This article has 421 citations.](https://doi.org/10.1073/pnas.98.3.974)

[7. (Lin2000Smurf2) Xia Lin, Min Liang, and Xin-Hua Feng. Smurf2 is a ubiquitin e3 ligase mediating proteasome-dependent degradation of smad2 in transforming growth factor-β signaling. Journal of Biological Chemistry, 275(47):36818–36822, November 2000. URL: http://dx.doi.org/10.1074/jbc.c000580200, doi:10.1074/jbc.c000580200. This article has 399 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1074/jbc.c000580200)

[8. (David2014Smurf2) Diana David, Sankar Jagadeeshan, Ramkumar Hariharan, Asha Sivakumari Nair, and Radhakrishna Madhavan Pillai. Smurf2 e3 ubiquitin ligase modulates proliferation and invasiveness of breast cancer cells in a cnksr2 dependent manner. Cell Division, August 2014. URL: http://dx.doi.org/10.1186/1747-1028-9-2, doi:10.1186/1747-1028-9-2. This article has 29 citations and is from a peer-reviewed journal.](https://doi.org/10.1186/1747-1028-9-2)

[9. (Ray2020Ubiquitin) Paramita Ray, Krishnan Raghunathan, Aarif Ahsan, Uday Sankar Allam, Shirish Shukla, Venkatesha Basrur, Sarah Veatch, Theodore S. Lawrence, Mukesh K. Nyati, and Dipankar Ray. Ubiquitin ligase smurf2 enhances epidermal growth factor receptor stability and tyrosine-kinase inhibitor resistance. Journal of Biological Chemistry, 295(36):12661–12673, September 2020. URL: http://dx.doi.org/10.1074/jbc.ra120.013519, doi:10.1074/jbc.ra120.013519. This article has 11 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1074/jbc.ra120.013519)

[10. (Osmundson2009Smurf2) Evan C Osmundson, Dipankar Ray, Finola E Moore, and Hiroaki Kiyokawa. Smurf2 as a novel mitotic regulator: from the spindle assembly checkpoint to tumorigenesis. Cell Division, July 2009. URL: http://dx.doi.org/10.1186/1747-1028-4-14, doi:10.1186/1747-1028-4-14. This article has 8 citations and is from a peer-reviewed journal.](https://doi.org/10.1186/1747-1028-4-14)

[11. (ZHANG2015miR15b) WEN-LONG ZHANG, JIAN-HUA ZHANG, XI-ZHAO WU, TAO YAN, and WEI LV. Mir-15b promotes epithelial-mesenchymal transition by inhibiting smurf2 in pancreatic cancer. International Journal of Oncology, 47(3):1043–1053, July 2015. URL: http://dx.doi.org/10.3892/ijo.2015.3076, doi:10.3892/ijo.2015.3076. This article has 52 citations and is from a peer-reviewed journal.](https://doi.org/10.3892/ijo.2015.3076)

[12. (Bai2020The) Yangjinming Bai and Ying Ying. The post-translational modifications of smurf2 in tgf-β signaling. Frontiers in Molecular Biosciences, July 2020. URL: http://dx.doi.org/10.3389/fmolb.2020.00128, doi:10.3389/fmolb.2020.00128. This article has 21 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fmolb.2020.00128)

[13. (Yu2020Ubiquitinationmediated) Le Yu, Ling Dong, Hui Li, Zhaojian Liu, Zhong Luo, Guangjie Duan, Xiaotian Dai, and Zhenghong Lin. Ubiquitination-mediated degradation of sirt1 by smurf2 suppresses crc cell proliferation and tumorigenesis. Oncogene, 39(22):4450–4464, May 2020. URL: http://dx.doi.org/10.1038/s41388-020-1298-0, doi:10.1038/s41388-020-1298-0. This article has 63 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1038/s41388-020-1298-0)